# US 2024/0189612 A1 · Methods for treating glioblastoma or recurrent glioblastoma utilizing a wireless signal alone or in combination with one or more cancer drugs, and associated systems, apparatuses, and devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189612 A1
- Document ID: US20240189612A1
- Status: Published application
- Kind: A1
- Application number: 18/227,298
- Filed: 2023-07-27
- Published: 2024-06-13
- Earliest claimed: 2017-10-04
- Assignees: EMulate Therapeutics, Inc.
- Applicants: EMulate Therapeutics, Inc.
- Inventors: Bennett Michael Butters
- Web page: https://patentgrep.com/patent/US20240189612A1

## CPC

- A61N 1/40: Applying electric fields by inductive or capacitive coupling (microwave apparatus A61N5/00); {Applying radio-frequency signals}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 1/323: {Interference currents, i.e. treatment by several currents summed in the body}
- A61N 1/36002: {Cancer treatment, e.g. tumour}
- A61N 2/004: {specially adapted for a specific therapy}
- A61P 35/00: Antineoplastic agents
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- G01N 37/005: {Measurement methods not based on established scientific theories}
- A61N 2/002: {in combination with another treatment}
- A61N 2/02: using magnetic fields produced by coils, including single turn loops or electromagnets (A61N2/12 takes precedence)
- A61N 5/022: {Apparatus adapted for a specific treatment}
- C12N 2310/14: interfering nucleic acids [NA]
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are methods and systems for treating cancer including glioblastoma, recurrent glioblastoma, or newly diagnosed glioblastoma, using the administration of ultra-low radio frequency energy (u/RFE®), either alone or in combination with one or more conventional cancer therapies. In some embodiments, the one or more conventional cancer therapies include chemotherapy or an anti-angiogenic therapy or other therapies.

## Claims

### Claim 1

A method of treating glioblastoma or recurrent glioblastoma in a subject comprising administering to the subject one or more u/RFE® signals.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more u/RFE® signals are administered using the Nativis Voyager® system.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administering to the subject a chemotherapy or an anti-angiogenic therapy or other cancer therapy.

### Claim 4 (depends on 3)

The method of claim 3, wherein the anti-angiogenic therapy is Avastin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more u/RFE® signals further comprises two signals.

### Claim 6 (depends on 1)

The method of claim 1, wherein the one or more u/RFE® signals further comprises three signals.

### Claim 7 (depends on 1)

The method of claim 1, wherein the one or more u/RFE® signals further comprises three or more signals.

### Claim 8

A method of treating newly diagnosed glioblastoma in a subject comprising administering to the subject one or more u/RFE® signals.

### Claim 9 (depends on 8)

The method of claim 8, wherein the subject is also being treated with a chemotherapy or radiotherapy.

### Claim 10 (depends on 9)

The method of claim 9, wherein the treatment with chemotherapy further comprises administering temozolomide to the subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the temozolomide is administered to the subject before, during, and/or after administration of the one or more u/RFE® signals.

### Claim 12 (depends on 8)

The method of claim 8, wherein the subject does not exhibit any serious adverse events after administration of the one or more u/RFE® signals.

### Claim 13 (depends on 8)

The method of claim 8, wherein each of the one or more u/RFE® signals are derived from a mitotic inhibitor or an siRNA molecule.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mitotic inhibitor is a taxane-derivative.

### Claim 15 (depends on 14)

The method of claim 14, wherein the taxane-derivative is taxol or paclitaxel.

### Claim 16 (depends on 13)

The method of claim 13, wherein the siRNA molecule is an siRNA molecule targeting CTLA-4 or PD-1.

### Claim at position 17

-26. (canceled)
